White House Order Boosts Definium’s DT120 Psychedelic Therapy Approval Pathway
Definium Therapeutics endorsed the White House Executive Order mandating coordinated federal efforts to prioritize mental health therapies, streamline psychedelic medicine regulatory pathways and expand access. The order could accelerate FDA review of Definium’s DT120 (lysergide tartrate) ODT program targeting GAD and MDD, enhancing prospects for its late-stage clinical pipeline.
1. Executive Order Provisions
The Executive Order directs coordinated federal action to prioritize novel mental health therapies, streamline regulatory pathways for psychedelic medicines and expand cross-agency collaboration. It calls for accelerated research models and evidence-based reviews to increase patient access to innovative treatments for serious mental illnesses.
2. Definium’s DT120 Clinical Program
DT120 ODT is Definium’s proprietary lysergide tartrate formulation using fast-dissolve Zydis® technology to improve absorption and reduce gastrointestinal side effects. The company is advancing DT120 in late-stage trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD), and is exploring additional neurological indications.
3. Potential Regulatory Impacts
By mandating faster and more coordinated FDA and agency reviews, the order may shorten approval timelines for psychedelic therapies. Definium anticipates that streamlined pathways and federal support will accelerate DT120’s transition from clinical evaluation to commercial availability.
4. Company Outlook and Strategy
Definium reaffirms its commitment to rigorous clinical science and collaboration with federal agencies, clinicians and patient communities. The company aims to leverage the Executive Order’s regulatory momentum to optimize its pipeline, potentially driving shareholder value through expedited development milestones.